Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.

@article{Simon2006IncreasedBO,
  title={Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.},
  author={George R. Simon and Christopher R. Garrett and Stephen C. Olson and Michael Langevin and Irene A. Eiseman and J Joseph Mahany and Charles C. Williams and Richard Lush and Adil I Daud and Pamela N. Munster and Alberto A. Chiappori and Mayer N. Fishman and Gerold Bepler and Peter F. Lenehan and Daniel Sullivan},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2006},
  volume={12 15},
  pages={
          4645-51
        }
}
PURPOSE In phase I studies with oral CI-1033, dose-limiting toxicities were primarily gastrointestinal, supporting the exploration of i.v. dosing to achieve optimal drug exposures by increasing bioavailability. EXPERIMENTAL DESIGN Fifty-three patients with advanced nonhematologic malignancies received i.v. CI-1033 via 30-minute infusions (10-500 mg) on a thrice-weekly schedule. Pharmacokinetic samples were collected on days 1 and 8 and evaluated using noncompartmental analysis. RESULTS Dose… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005

Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2005

Administra - tion of CI - 1033 , an irreversible pan - erbB tyrosine kinase inhibitor , is feasible on a 7 - day on , 7 - day off schedule : a phase I pharmacokinetic and food effect study

E Calvo, TolcherAW, LA Hammond
  • Clin Cancer Res
  • 2004

The biology of epidermal growth factor receptor in lung cancer.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2004